Capitol Perspectives
-
Bloated COVID Relief Package Misses Mark
3/8/2021
In his final column, John McManus discusses the difficult position pharma companies are in now from a political standpoint and the COVID relief bills.
-
New Swipes At Rx Industry Despite Stable Costs
2/8/2021
On the last full day of President Trump’s tumultuous presidency, CMS released a proposal to dramatically restrict access to Part D drugs for patients with serious medical conditions.
-
Most Favored Nation Pricing Temporarily Halted By Courts
1/14/2021
In late December, the courts halted President Trump’s international reference-pricing scheme, the Most Favored Nation model, saying the administration had improperly attempted to implement a radical change in Medicare reimbursement policy.
-
Most Favored Nation Regulation Could Upend The Rx Market
12/9/2020
Buried on page 184 of President Trump’s interim final rule (IFR) implementing his “Most Favored Nation” (MFN) drug proposal is Table 11, which projects 19% lower utilization of Medicare Part B medications due to “no access.”
-
Election Fallout: Can Divided Government Forge Bipartisan Solutions?
11/10/2020
As the election concludes, we still face new changes to healthcare policy, pharma price-controls, taxes, and a staggering debt.
-
Implementation Of MFN, Importation, And Other Mischief In 2020
10/12/2020
As the election nears and a potential change in power of both the White House and Congress approaches, it is important to understand that significant healthcare policy can still be accomplished this year.
-
Democratic And Republican Health Priorities In The Next Administration
9/9/2020
With the conventions and a contentious summer behind them, both political parties are laying out their agendas for the next four years. What are the Democratic and Republican health priorities?
-
Trump Threatens Rx Industry With Executive Orders
8/11/2020
As Trump’s one-month deadline for a deal with PhRMA ticks away, nervous pharmaceutical executives are equally dismissive and anxious about the next actions of an often-impulsive president.
-
Democratic House Passes Rx Price Controls Amid Pandemic
7/10/2020
During this COVID-19 crisis, government should be collaborating closely with industry to promote innovation that will save lives, improve health and bring back prosperity that can come with safely reopening the economy. Yet, it is astonishing that House Democrats have chosen the opposite path.
-
More Nuanced Approach Needed To Fight COVID-19
5/29/2020
When will COVID-based decisions by politicians be guided by mounting data that suggests targeted approaches to containing the pandemic would be beneficial for both the vulnerable and the rest of the population, which must get on living their lives and providing for their families.